One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
Christie M. Ballantyne, MD,a Puja Banka, MD,b Gustavo Mendez, MD, c Raymundo Garcia, MD, d Julio Rosenstock, MD,e Anthony Rodgers, MS,b Geraldine Mendizabal, MD,b Yale Mitchel, MD,b Alberico L. Catapano, MD HC, PHD
doi : 10.1016/j.jacc.2023.02.018
Volume 81, Issue 16, 25 April 2023, Pages 1553-1564
MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia.
Realizing the Potential of PCSK9 Inhibition: A Novel Oral Macrocyclic Peptide on the Horizon∗
M. John Chapman, BSC (HONS), P HD, DS C, a,b,c Chris J. Packard, BS C (HONS), P HD, DS C
doi : 10.1016/j.jacc.2023.03.384
Volume 81, Issue 16, 25 April 2023, Pages 1565-1568
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer
Alessia Lena, MD, a,b,c,d Ursula Wilkenshoff, MD,a,b,e Sara Hadzibegovic, MD,a,b,c,d Jan Porthun, MMMS C ,b,f,g Lukas R?snick, b,c,d,f Ann-Kathrin Fr?hlich, b,c,d,f Tanja Zeller, P HD, h,i,j Mahir Karakas, MD, P HD, MBA, j,k Ulrich Keller, MD, l,m,n Johann Ahn, MD,o Lars Bullinger, MD,m,o Hanno Riess, MD, p Stuart D. Rosen, MD, q,r,s Alexander R. Lyon, MD, PHD, q Thomas F. Lüscher, MD,q,r,s,t Matthias Totzeck, MD, u Tienush Rassaf, MD, u Daniel Burkhoff, MD, PH D, v Mandeep R. Mehra, MD, MS C,w Jeroen J. Bax, MD, PH D, x,y Javed Butler, MD, MPH, MBA, z,aa Frank Edelmann, MD,b,c,e,f Wilhelm Haverkamp, MD,c,d,bb Stefan D. Anker, MD, P HD, c,d,bb Milton Packer, MD, cc Andrew J.S. Coats, DM, DS C , MBA, dd Stephan von Haehling, MD, PHD, ee,ff Ulf Landmesser, MD,a,b,c,e Markus S. Anker, MD
doi : 10.1016/j.jacc.2023.02.039
Volume 81, Issue 16, 25 April 2023, Pages 1569-1586
The frequency, extent, and clinical and prognostic importance of cardiac wasting in cancer patients is unknown.
New Insights Into Cardiac Wasting in Patients With Cancer∗
Aarti Asnani, MD
doi : 10.1016/j.jacc.2023.02.035
Volume 81, Issue 16, 25 April 2023, Pages 1587-1589
Exercise Capacity, NT-proBNP, and Exercise Hemodynamics in Adults Post-Fontan
William R. Miranda, MD, C. Charles Jain, MD, Barry A. Borlaug, MD, Allan S. Jaffe, MD, Heidi M. Connolly, MD, Luke J. Burchill, MD, PHD, Alexander C. Egbe, MBBS
doi : 10.1016/j.jacc.2023.02.031
Volume 81, Issue 16, 25 April 2023, Pages 1590-1600
Cardiopulmonary exercise testing (CPET) and N-terminal pro–B-type natriuretic peptide (NT-proBNP) measurement are frequently performed in adults post-Fontan, but their correlations with exercise invasive hemodynamics are poorly understood. Moreover, whether exercise cardiac catheterization provides incremental prognostic information is unknown.
Invasive Cardiopulmonary Exercise Testing in Patients With Fontan Circulation∗
Alfred Hager, MD
doi : 10.1016/j.jacc.2023.03.380
Volume 81, Issue 16, 25 April 2023, Pages 1601-1604
Long-Term Health Care Utilization After Cardiac Surgery in Children Covered Under Medicaid
Sarah Crook, PH D, a Kacie Dragan, MPH,b,c Joyce L. Woo, MD, MS, d Matthew Neidell, P HD, e Pengfei Jiang, MS, a Stephen Cook, MD, MPH,f,g Edward L. Hannan, P HD, h Jane W. Newburger, MD, MPH,i Marshall L. Jacobs, MD, j Emile A. Bacha, MD, k Christopher J. Petit, MD, a Robert Vincent, MD,l Kathleen Walsh-Spoonhower, MD, m Ralph Mosca, MD, n T. K. Susheel Kumar, MD,n Neil Devejian, MD,o Steven A. Kamenir, MD, p George M. Alfieris, MD, q,r Michael F. Swartz, PH D, q David Meyer, MD, MS, s Erin A. Paul, MD, t John Billings, JD, b Brett R. Anderson, MD, MBA, MS, a on behalf of New York State CHS-COLOUR
doi : 10.1016/j.jacc.2023.02.021
Volume 81, Issue 16, 25 April 2023, Pages 1605-1617
Understanding the longitudinal burden of health care expenditures and utilization after pediatric cardiac surgery is needed to counsel families, improve care, and reduce outcome inequities.
Health Care Expenditures in Cardiac Children: The Time to Act Is Now∗
Mitchell I. Cohen, MD, a Jamie E. Cohen, BA, b James St. Louis, MD
doi : 10.1016/j.jacc.2023.03.379
Volume 81, Issue 16, 25 April 2023, Pages 1618-1620
Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3
Daein Choi, MD,a,b Waqas A. Malick, MD, b Wolfgang Koenig, MD, c,d,e Daniel J. Rader, MD,f Robert S. Rosenson, MD
doi : 10.1016/j.jacc.2023.02.038
Volume 81, Issue 16, 25 April 2023, Pages 1621-1632
The availability of statins, ezetimibe, and PCSK9 inhibitors has significantly improved the prognosis of familial hypercholesterolemia (FH). However, a great number of individuals with FH do not achieve guideline-recommended low-density lipoprotein (LDL) cholesterol levels despite maximal lipid-lowering therapy.
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3
Waqas A. Malick, MD, a Sascha N. Goonewardena, MD, b Wolfgang Koenig, MD, c,d Robert S. Rosenson, MD
doi : 10.1016/j.jacc.2023.02.033
Volume 81, Issue 16, 25 April 2023, Pages 1633-1645
Lipoprotein(a) [Lp(a)] is a source of residual risk in patients with atherosclerotic cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies targeting proprotein convertase subtilisin kexin 9 have shown that reductions in Lp(a) concentrations may be a predictor of event reduction with this class of cholesterol-lowering therapy.
Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies: JACC Focus Seminar 3/3
Waqas A. Malick, MD, a Ori Waksman, MD,a Ron Do, P HD, b Wolfgang Koenig, MD, c,d Aruna D. Pradhan, MD, MPH,e,f Erik S.G. Stroes, MD, P HD, g Robert S. Rosenson, MD
doi : 10.1016/j.jacc.2023.02.034
Volume 81, Issue 16, 25 April 2023, Pages 1646-1658
Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have either failed to reduce major adverse cardiovascular events or shown no linkage of TG reduction with event reduction, particularly when these agents were tested on a background of statin therapy. Limitations in trial design may explain this lack of efficacy.
Effect of Lifestyle Modification and Green Mediterranean Diet on Proximal Aortic Stiffness
Gal Tsaban, MD, MPH Aryeh Shalev, MD Amos Katz, MD Anat Yaskolka Meir, RD, PhD Ehud Rinott, MD, PhD Hila Zelicha, RD, PhD Alon Kaplan, MD, PhD Arik Wolak, MD Matthias Bluher, MD, PhD Meir J. Stampfer, MD, DrPh *Iris Shai, RD, PhD
doi : 10.1016/j.jacc.2023.02.032
Volume 81, Issue 16, 25 April 2023, Pages 1659-1661
Atrial Fibrillation, Tricuspid Regurgitation, and Pacemaker: A Vicious Circle
Stefano Bonapace, MD Alessio Marinelli, MD Alessandro Costa, MD Konstantinos Trachanas, MD Giulio Molon, MD
doi : 10.1016/j.jacc.2022.12.032
Volume 81, Issue 16, 25 April 2023, Page e139
Reply: Atrial Fibrillation, Tricuspid Regurgitation, and Pacemaker: A Vicious Circle
Sri Harsha Patlolla, MBBS, MS *Hartzell V. Schaff, MD
doi : 10.1016/j.jacc.2023.01.047
Volume 81, Issue 16, 25 April 2023, Page e141
